Soleus Capital Management, L.P.

http://soleuscapital.com/

Last activity: 20.08.2026

Active

Categories: FinTechFirmHealthTechInvestmentLifePublicSpace

The Firm seeks to generate superior risk-adjusted returns through idiosyncratic, catalyst-driven investing with a focus on complex and niche opportunities in the Public and Private space.

Mentions

Overview

Employees

11-50

Founded date

2018

Mentions in press and media 21

Date	Title	Description
Sign up to see	Sign up to see	Sign up to see
Aug 20, 2026	Bridge To Life Raises $110 Million To Scale FDA-Cleared VitaSmart Liver Perfusion System And Expand Organ Transplant Pipeline	Bridge to Life has completed $110 million in Series C equity and debt financing to accelerate the U.S. commercialization of its VitaSmart Hypothermic Oxygenated Perfusion System and advance a broader pipeline of organ preservation and viabi...
Aug 18, 2026	Abcuro Raises $66M in Series D Funding	Abcuro, a Newton, MA-based clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases through precise modulation of cytotoxic T cells, raised $66M in Series D funding. The round was led by New Leaf Ve...
Aug 16, 2026	AI Powers Record VC Rounds, Strategic Tech Gains Momentum	Venture capital aggressively backs artificial intelligence and strategic deep technologies. Databricks leads with a monumental $5 billion raise, solidifying enterprise AI's critical role and market dominance. Geopolitical currents stee...
Aug 13, 2026	Venture Capital & Startup Funding Roundup, August 13, 2026: Blackstone, Coatue, Founders Fund, Sequoia Capital, Thiel Capital & More	Venture dollars are again clustering around AI and infrastructure. Today’s biggest deal saw Databricks haul in a record-breaking $5 billion at a $190 billion valuation. That massive raise – led by Coatue, Blackstone, MGX, T. Rowe Price, and...
Aug 12, 2026	Bridge to Life Raises $110M in Series C Funding	Bridge to Life Ltd., a Northbrook, Illinois-based provider of organ preservation solutions and perfusion technologies, raised $110M in Series C and debt financing. The round was led by Soleus Capital with participation from Lauxera Capital ...
Jul 24, 2026	Crystalys Therapeutics Announces $130 Million Series B Financing To Advance Gout Treatment Dotinurad	Crystalys Therapeutics announced the closing of an oversubscribed $130 million Series B financing to support late-stage global clinical development and commercialization preparation of dotinurad, a next-generation, once-daily, oral URAT1 in...
Jul 22, 2026	Crystalys Therapeutics Raises $130 Million To Bring Late-Stage Gout Drug To U.S. Market	Crystalys Therapeutics raises $130 million in an oversubscribed Series B financing round. The funding will help Crystalys take its late-stage gout drug to market. Series B comes less than a year after its impressive $205 million Series A of...
Jan 11, 2026	Parabilis Medicines Secures $305 Million for Cancer Drug Revolution	Parabilis Medicines recently closed an oversubscribed $305 million Series F financing round. This substantial capital propels its lead cancer candidate, zolucatetide, towards pivotal clinical trials for desmoid tumors and other challenging ...
Jan 8, 2026	Parabilis rockets ahead with $305M series F to 'upend the status quo' with tumor drug	Parabilis Medicines is taking an early lead in the 2026 biotech fundraising race, closing a $305 million series F round that will fuel a pivotal push for its potential first-in-class cancer drug. The funds come from a smorgasbord of existin...
Jan 8, 2026	Parabilis Medicines Raises $305M Series F Funding	Parabilis Medicines, a Cambridge, MA-based clinical-stage biopharmaceutical company committed to creating medicines for people living with cancer, closed a $305m Series F financing. The round was co-led by RA Capital Management, Fidelity Ma...
Jan 8, 2026	Parabilis Medicines: $305 Million Series F Raised To Advance Zolucatetide Program And Helicon Peptide Platform	Parabilis Medicines, a clinical-stage cancer drug developer, said it has closed an oversubscribed $305 million Series F financing to fund ongoing clinical development of its lead candidate FOG-001 (zolucatetide) across multiple tumor types ...
Oct 12, 2025	Star Therapeutics: $125 Million Series D Raised For Developing Antibodies For Bleeding Disorders	Star Therapeutics, an innovative clinical-stage biotechnology company, is dedicated to discovering and developing cutting-edge antibodies aimed at treating bleeding disorders and other medical conditions. The company recently announced the ...
Oct 1, 2025	Star Therapeutics Raises $125M in Series D Financing	Star Therapeutics, a San Francisca, CA-based clinical stage biotechnology company discovering and developing antibodies for bleeding disorders and other diseases, raised $125M Series D funding. The round was co-led by Sanofi Ventures and Vi...
May 29, 2025	Pillar Biosciences Secures $34.5 Million to Propel Decision Medicine Forward	Pillar Biosciences is on the rise. The Natik, Massachusetts-based company has secured $34.5 million in funding. This infusion comes from a mix of strategic investors, including Illumina and Soleus Capital. The goal? To enhance their Decisio...
May 29, 2025	Pillar Biosciences: $34.5 Million Raised For Decision Medicine Platform	Pillar Biosciences, a leader in Decision Medicine, announced they have finalized $34.5 million in funding, including a strategic investment from Illumina, structured financing from Soleus Capital, and investments from existing investors. Ho...
Feb 24, 2025	OrganOx Closes $142M Equity Financing	OrganOx, an Oxford, UK-based organ medical technology company, raised $142M in equity funding. The round was led by new investor HealthQuest Capital with participation from existing investors BGF and Lauxera Capital Partners, along with add...
Feb 19, 2025	Abcuro: $200 Million (Series C) Raised For Advancing Medicine In Development For Inclusion Body Myositis	Abcuro – a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells – announced the closing of a $200 million Series C financing led by New...
Nov 15, 2024	The Surge of Innovation: Beta Bionics and PMWeb Secure Major Investments	In the fast-paced world of technology and healthcare, two companies have recently made headlines by securing significant funding. Beta Bionics and PMWeb are not just raising capital; they are paving the way for transformative solutions in d...
Nov 15, 2024	Beta Bionics Closes $60M Series E Financing	Beta Bionics, an Irvine, CA-based company which specializes in the development of advanced diabetes management solutions, raised $60M in Series E funding. The round was led by Wellington Management. Previous investors Eventide Asset Managem...
Aug 13, 2020	Mission Bio Lands $70M to Expand Cancer Therapies With Single-Cell Multi-Omics Platform	What You Should Know: – Mission Bio raises $70 million in Series C funding led by Novo Growth to accelerate the development of cancer therapies with single-cell multi-omics. – Mission Bio’s Tapestri Platform, the first single-cell platform ...

Reviews 0

FAQ about Soleus Capital Management, L.P.

When was Soleus Capital Management, L.P. founded?

Soleus Capital Management, L.P. was founded in 2018.

What has the press written about Soleus Capital Management, L.P.?

Parsers VC has collected 21 articles mentioning Soleus Capital Management, L.P., among them “Bridge To Life Raises $110 Million To Scale FDA-Cleared VitaSmart Liver Perfusion System And Expand Organ Transplant Pipeline” (Aug 20, 2026) and “Abcuro Raises $66M in Series D Funding” (Aug 18, 2026).

Is Soleus Capital Management, L.P. still active?

Yes, Soleus Capital Management, L.P. is active; its latest activity on Parsers VC dates from Aug 20, 2026.